JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 84 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $4,687,000 | -34.7% | 1,407,159 | -2.9% | 0.00% | -50.0% |
| Q2 2019 | $7,173,000 | -23.0% | 1,449,194 | -3.5% | 0.00% | 0.0% |
| Q1 2019 | $9,313,000 | +82.9% | 1,502,158 | -0.6% | 0.00% | +100.0% |
| Q4 2018 | $5,091,000 | -52.5% | 1,510,754 | -8.4% | 0.00% | -50.0% |
| Q3 2018 | $10,723,000 | -29.8% | 1,649,753 | -17.3% | 0.00% | -33.3% |
| Q2 2018 | $15,280,000 | -67.0% | 1,994,704 | -3.8% | 0.00% | -70.0% |
| Q1 2018 | $46,321,000 | +93.8% | 2,072,483 | +10.5% | 0.01% | +100.0% |
| Q4 2017 | $23,905,000 | -18.4% | 1,874,862 | -0.3% | 0.01% | -28.6% |
| Q3 2017 | $29,305,000 | -14.4% | 1,880,962 | -22.9% | 0.01% | -12.5% |
| Q2 2017 | $34,243,000 | -1.6% | 2,440,716 | +54.2% | 0.01% | 0.0% |
| Q1 2017 | $34,814,000 | – | 1,583,185 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 4,447,829 | $30,245,000 | 89.29% |
| TRV GP III, LLC | 3,048,780 | $20,732,000 | 3.62% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 250,644 | $1,704,000 | 0.76% |
| PFM Health Sciences, LP | 3,262,833 | $22,187,000 | 0.70% |
| Yorktown Management & Research Co Inc | 56,600 | $385,000 | 0.30% |
| Sofinnova Investments, Inc. | 624,756 | $4,248,000 | 0.24% |
| Omega Fund Management, LLC | 275,513 | $1,873,000 | 0.21% |
| PATHWAY CAPITAL MANAGEMENT, LP | 60,279 | $410,000 | 0.16% |
| Orbimed Advisors | 2,147,400 | $14,602,000 | 0.15% |
| Grace Capital | 18,669 | $127,000 | 0.08% |